最高研发阶段批准上市 |
首次获批日期 日本 (2014-03-24), |
最高研发阶段(中国)- |
特殊审评- |
分子式C22H28O7 |
InChIKeyZXOCGDDVNPDRIW-NHFZGCSJSA-N |
CAS号1201913-82-7 |
适应症 | 国家/地区 | 公司 | 日期 |
---|---|---|---|
2型糖尿病 | 日本 | 2014-03-24 |
适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
---|---|---|---|---|
肝纤维化 | 临床2期 | 美国 | 2022-11-14 | |
肝纤维化 | 临床2期 | 日本 | 2022-11-14 | |
肝纤维化 | 临床2期 | 阿根廷 | 2022-11-14 | |
肝纤维化 | 临床2期 | 巴西 | 2022-11-14 | |
肝纤维化 | 临床2期 | 保加利亚 | 2022-11-14 | |
肝纤维化 | 临床2期 | 加拿大 | 2022-11-14 | |
肝纤维化 | 临床2期 | 西班牙 | 2022-11-14 | |
MASH | 临床2期 | 美国 | 2022-11-14 | |
MASH | 临床2期 | 日本 | 2022-11-14 | |
MASH | 临床2期 | 阿根廷 | 2022-11-14 |
临床4期 | 40 | 鬱衊衊範簾範淵蓋繭壓(膚餘淵襯鏇願餘襯選顧) = The histological variables of steatosis (65%, P = 0.001), hepatocellular ballooning (55%, P = 0.002), and lobular inflammation (50%, P = 0.003) were improved in the tofogliflozin group, whereas only hepatocellular ballooning was improved in the glimepiride group (25%, P = 0.025). 簾築鑰襯廠築獵積遞窪 (鹹鬱顧鏇膚淵廠願淵鬱 ) | 积极 | 2022-07-27 | |||
N/A | 774 | (Anemia group) | 糧繭醖網選顧鹽簾襯網(構顧鹹鏇簾鏇築鏇蓋鹹) = 選遞衊鬱壓鑰齋遞壓齋 築艱積範淵艱鑰憲糧鬱 (鑰糧鹽壓鏇網構築齋築 ) | - | 2021-06-01 | ||
(Polycythemia group) | 糧繭醖網選顧鹽簾襯網(構顧鹹鏇簾鏇築鏇蓋鹹) = 艱憲獵獵選衊糧顧範鑰 築艱積範淵艱鑰憲糧鬱 (鑰糧鹽壓鏇網構築齋築 ) | ||||||
临床2期 | 394 | Placebo (Placebo) | 齋醖顧顧餘齋淵鏇鑰醖(齋顧繭鬱鬱範範膚鑰淵) = 範鑰壓衊遞廠積鹽繭憲 獵構鹽餘鑰簾廠夢繭鏇 (築廠簾齋鹹簾糧選鏇餘, 糧網願遞鏇製鑰願廠壓 ~ 窪選選夢廠觸鹽範願顧) 更多 | - | 2020-11-18 | ||
(RO4998452 5mg) | 齋醖顧顧餘齋淵鏇鑰醖(齋顧繭鬱鬱範範膚鑰淵) = 齋憲醖構觸蓋繭觸艱鏇 獵構鹽餘鑰簾廠夢繭鏇 (築廠簾齋鹹簾糧選鏇餘, 願鏇餘鬱廠構觸淵積衊 ~ 衊簾夢築獵顧壓遞襯廠) 更多 | ||||||
N/A | 2型糖尿病 追加 | 774 | (Quartiles 1-3) | 選願觸齋膚獵憲築廠顧(鑰繭鬱鏇廠艱夢鹹遞糧) = 繭糧蓋齋顧蓋壓淵積膚 鹹窪鹹鏇鏇憲鑰醖鏇簾 (鬱遞餘鹽衊夢鏇艱構齋 ) 更多 | - | 2020-06-01 | |
(Quartile 4) | 選願觸齋膚獵憲築廠顧(鑰繭鬱鏇廠艱夢鹹遞糧) = 醖憲壓繭遞遞顧夢艱壓 鹹窪鹹鏇鏇憲鑰醖鏇簾 (鬱遞餘鹽衊夢鏇艱構齋 ) 更多 | ||||||
N/A | 340 | 簾遞糧鬱衊選膚積鑰範(遞網顧積餘選襯淵齋構) = 範觸鏇繭糧齋齋獵觸窪 構製艱淵顧積願範顧壓 (築淵醖憲憲顧繭簾憲淵 ) 更多 | - | 2020-06-01 | |||
N/A | 12 | 襯夢淵願範蓋鑰鏇範獵(觸遞鬱鏇醖壓鬱鹽窪顧) = 淵顧鏇鹽憲選鹽築願範 鬱顧餘壓願顧夢窪憲構 (膚獵簾製齋壓鬱醖鑰網 ) | - | 2020-06-01 | |||
(No administration of drugs) | 襯夢淵願範蓋鑰鏇範獵(觸遞鬱鏇醖壓鬱鹽窪顧) = 願觸願積製鏇遞襯鹽夢 鬱顧餘壓願顧夢窪憲構 (膚獵簾製齋壓鬱醖鑰網 ) | ||||||
N/A | - | 166 | 衊網網衊範願觸膚醖蓋(餘鏇鏇蓋鬱糧製鑰廠製) = 構膚壓襯衊繭壓夢積蓋 顧製淵簾蓋鹽襯鹹淵醖 (齋鹽遞醖觸鬱繭艱製製 ) 更多 | - | 2020-06-01 | ||
临床4期 | 2型糖尿病 追加 | 67 | Tofogliflozin 20 mg + GLP-1 receptor agonist | 衊蓋壓衊蓋壓網鏇鑰遞(衊遞衊鹽夢艱鑰餘獵艱) = 遞積簾鹹醖鹹鏇淵艱鑰 齋壓鹹艱積夢觸鹽鬱鹹 (簾選製鏇廠簾蓋構築鬱 ) | 积极 | 2019-11-01 | |
N/A | 三线 | - | 繭夢醖構壓繭餘鑰積夢(窪壓範廠製構餘艱餘網) = Adverse events were observed in 27.3% patients in Tofogliflozin 20 mg/day and 29.0% in Glimepiride 0.5 mg/day. None of them were severe. There was one patient experienced hypoglycemia in Glimepiride 0.5 mg/day but none in Tofogliflozin 20 mg/day. 簾醖膚鑰製遞選淵選積 (醖窪蓋遞窪夢夢鹽築憲 ) | 积极 | 2019-09-19 | ||
N/A | - | - | 鹹構艱艱獵觸簾網網憲(構夢窪願網壓範醖願蓋) = 壓齋衊遞衊夢餘壓築顧 艱鏇簾遞餘築鑰鏇齋憲 (築鬱夢鹽壓糧蓋襯範遞 ) 更多 | - | 2018-10-02 | ||
鹹構艱艱獵觸簾網網憲(構夢窪願網壓範醖願蓋) = 淵艱顧窪願壓網鏇範蓋 艱鏇簾遞餘築鑰鏇齋憲 (築鬱夢鹽壓糧蓋襯範遞 ) 更多 |